Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Age-Related Differences in Non-Persistence with Statin Treatment in Patients after a Transient Ischaemic Attack

M. Wawruch, D. Zatko, G. Wimmer, J. Luha, S. Wimmerova, P. Matalova, P. Kukumberg, J. Murin, T. Tesar, B. Havelkova, R. Shah,

. 2017 ; 37 (11) : 1047-1054.

Language English Country New Zealand

Document type Journal Article

E-resources Online Full text

NLK ProQuest Central from 2008-06-01 to 1 year ago
Health & Medicine (ProQuest) from 2008-06-01 to 1 year ago

BACKGROUND AND OBJECTIVE: Non-persistence with secondary preventive measures, including medications such as statins, adversely affects the prospects of successful outcomes. This study was aimed at evaluating non-persistence with statin therapy in cohorts of young and elderly patients after a transient ischaemic attack (TIA) and identifying patient-associated characteristics that influence the risk for non-persistence. METHODS: The study cohorts included 797 adult patients who were initiated on statin therapy following a TIA diagnosis between 1 January 2010 and 31 December 2010. Patients were followed up for 3 years and those with a treatment gap of at least a 6-month period were considered 'non-persistent'. In order to identify any age-related differences, all analyses were conducted in the entire study cohort (n = 797) as well as separately in the 'younger' (aged <65 years, n = 267) and the 'older' (aged ≥65 years, n = 530) patients. RESULTS: Non-persistence was significantly more common in younger patients compared to older patients (67.8% vs. 49.1%; p < 0.001). Factors that decreased the probability of non-persistence in younger and older patients included diabetes mellitus (hazard ratio [HR] = 0.72 and HR = 0.64, respectively) and hypercholesterolaemia (HR = 0.43 and HR = 0.62, respectively). Female gender (HR = 1.42) was associated with a higher and increasing number of medications taken (HR = 0.93), with lower probability for non-persistence in younger patients but not in the older patients. CONCLUSIONS: Our results indicate that certain patients with TIA require special counselling to improve persistence with statin therapy. These include younger patients, especially females and those not on polypharmacy, and both younger and older patients without diabetes mellitus or hypercholesterolaemia.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024750
003      
CZ-PrNML
005      
20180712100708.0
007      
ta
008      
180709s2017 nz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s40261-017-0559-3 $2 doi
035    __
$a (PubMed)28791591
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Wawruch, Martin $u Institute of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Comenius University, Sasinkova 4, 811 08, Bratislava, Slovakia. martin.wawruch@gmail.com.
245    10
$a Age-Related Differences in Non-Persistence with Statin Treatment in Patients after a Transient Ischaemic Attack / $c M. Wawruch, D. Zatko, G. Wimmer, J. Luha, S. Wimmerova, P. Matalova, P. Kukumberg, J. Murin, T. Tesar, B. Havelkova, R. Shah,
520    9_
$a BACKGROUND AND OBJECTIVE: Non-persistence with secondary preventive measures, including medications such as statins, adversely affects the prospects of successful outcomes. This study was aimed at evaluating non-persistence with statin therapy in cohorts of young and elderly patients after a transient ischaemic attack (TIA) and identifying patient-associated characteristics that influence the risk for non-persistence. METHODS: The study cohorts included 797 adult patients who were initiated on statin therapy following a TIA diagnosis between 1 January 2010 and 31 December 2010. Patients were followed up for 3 years and those with a treatment gap of at least a 6-month period were considered 'non-persistent'. In order to identify any age-related differences, all analyses were conducted in the entire study cohort (n = 797) as well as separately in the 'younger' (aged <65 years, n = 267) and the 'older' (aged ≥65 years, n = 530) patients. RESULTS: Non-persistence was significantly more common in younger patients compared to older patients (67.8% vs. 49.1%; p < 0.001). Factors that decreased the probability of non-persistence in younger and older patients included diabetes mellitus (hazard ratio [HR] = 0.72 and HR = 0.64, respectively) and hypercholesterolaemia (HR = 0.43 and HR = 0.62, respectively). Female gender (HR = 1.42) was associated with a higher and increasing number of medications taken (HR = 0.93), with lower probability for non-persistence in younger patients but not in the older patients. CONCLUSIONS: Our results indicate that certain patients with TIA require special counselling to improve persistence with statin therapy. These include younger patients, especially females and those not on polypharmacy, and both younger and older patients without diabetes mellitus or hypercholesterolaemia.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a kohortové studie $7 D015331
650    _2
$a diabetes mellitus $x epidemiologie $7 D003920
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a statiny $x terapeutické užití $7 D019161
650    _2
$a hypercholesterolemie $x farmakoterapie $7 D006937
650    _2
$a tranzitorní ischemická ataka $x farmakoterapie $7 D002546
650    _2
$a mužské pohlaví $7 D008297
650    12
$a adherence k farmakoterapii $7 D055118
650    _2
$a lidé středního věku $7 D008875
650    _2
$a polypharmacy $7 D019338
650    _2
$a proporcionální rizikové modely $7 D016016
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zatko, Dusan $u General Health Insurance Company, Panónska cesta 2, 851 04, Bratislava, Slovakia.
700    1_
$a Wimmer, Gejza $u Institute of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Comenius University, Sasinkova 4, 811 08, Bratislava, Slovakia.
700    1_
$a Luha, Jan $u Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Sasinkova 4, 811 08, Bratislava, Slovakia.
700    1_
$a Wimmerova, Sona $u Department of Biophysics, Informatics and Biostatistics, Faculty of Public Health, Slovak Medical University, Limbová 12, 833 03, Bratislava, Slovakia.
700    1_
$a Matalova, Petra $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 3, 775 15, Olomouc, Czech Republic.
700    1_
$a Kukumberg, Peter $u 2nd Department of Neurology, Faculty of Medicine, Comenius University, Limbová 5, 833 05, Bratislava, Slovakia.
700    1_
$a Murin, Jan $u 1st Department of Internal Medicine, Faculty of Medicine, Comenius University, Mickiewiczova 13, 813 69, Bratislava, Slovakia.
700    1_
$a Tesar, Tomas $u Department of Organisation and Management of Pharmacy, Faculty of Pharmacy, Comenius University, Kalinciakova 8, 832 32, Bratislava, Slovakia.
700    1_
$a Havelkova, Beata $u General Health Insurance Company, Panónska cesta 2, 851 04, Bratislava, Slovakia.
700    1_
$a Shah, Rashmi $u Independent Pharmaceutical Consultant, 8 Birchdale, Gerrards Cross, Buckinghamshire, SL9 7JA, UK.
773    0_
$w MED00001123 $t Clinical drug investigation $x 1179-1918 $g Roč. 37, č. 11 (2017), s. 1047-1054
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28791591 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180712101001 $b ABA008
999    __
$a ok $b bmc $g 1316881 $s 1021671
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 37 $c 11 $d 1047-1054 $i 1179-1918 $m Clinical drug investigation $n Clin. drug invest. $x MED00001123
LZP    __
$a Pubmed-20180709

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...